SHORT COMMUNICATIONDNA methylation in the 5-HTT regulatory region is associated with CO2-induced fear in panic disorder patients
Introduction
Panic attacks (PAs) are characterized by intense fear and physical symptoms, and strongly impair patients’ quality of life (Davidoff et al., 2012). Unexpected PAs represent the core symptom of panic disorder (PD) and are now listed as a severity specifier applicable to all mental disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM)−5 (American Psychiatric Association, 2013).
PAs can be reliably provoked in PD patients using a brief 35% CO2-inhalation, and interestingly also in healthy individuals when the CO2 dosage is increased (for review see Leibold et al., 2015). This suggests the existence of a CO2-sensitivity continuum in which PD patients are hypersensitive to CO2. By now, CO2-hypersensitivity is a well-validated endophenotype of PD. A series of studies linked this endophenotype to the serotonergic (5-HT) system. Briefly, tryptophan depletion to reduce 5-HT levels increased the panic response to CO2-inhalation (Schruers et al., 2000). In contrast, acute administration of the 5-HT precursor to increase 5-HT levels reduced the response to CO2 (Schruers et al., 2002). Next, natural variation in 5-HT levels was studied by focusing on functional polymorphisms that alter gene expression. Participants homozygous for the long (L)-allele of the serotonin transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR) reported the highest fear to CO2 (Schruers et al., 2011). The l-allele has been linked to a higher 5-HTT expression compared to the short (S)-allele (Lesch et al., 1996). In the brain, the 5-HTT is located on the presynaptic neuron and a higher expression leads to a relatively more efficient reuptake of 5-HT into the neuron, thereby affecting neurotransmission.
Research in the last few years has shown that not only static genetic variants contribute to how an individual's brain network is activated and works, but that gene expression is also influenced by environmental cues, mediated through dynamic epigenetic modifications (Guo et al., 2011). Genetically identical individuals can have a distinct risk to develop a disorder, as they have different gene expression and thus differently functioning networks caused by these epigenetic modifications. One of the most studied types of epigenetic regulation is DNA methylation occurring at cytosine residues. Although DNA methylation has gained attention in recent years, few studies have examined epigenetic modifications in PD. Only two genome-wide association studies (Iurato et al., 2017; Shimada-Sugimoto et al., 2017) and, based on evidence that the 5-HT system dysfunction is implicated in mental disorders, some candidate gene-based studies, focusing on crucial factors of the 5-HT system such as the monoamine oxidase A (MAO-A) gene, attempted to determine the involvement of DNA methylation in the etiology of PD (Domschke et al., 2012; Ziegler et al., 2016). Interestingly, although variation in the gene encoding the 5-HTT (SLC6A4) has been associated with PD and CO2-sensitivity, its methylation status has not yet been specifically examined in this context.
The aim of this study was to address this gap and to explore the relationship between DNA methylation in the regulatory region of the SLC6A4 gene and CO2-responsivity in PD patients, taking 5-HTT genotype into account. Previously, we showed that 5-HTTLPR l-allele carriers, presumably having a relatively higher expression of 5-HTT, displayed a stronger response to CO2 (Schruers et al., 2011). Based on this, we hypothesized that relatively lower DNA methylation levels, generally considered to be concomitant with a higher gene transcription and thus 5-HTT expression, were associated with higher CO2-reactivity.
Section snippets
Experimental procedures
All experimental procedures were approved by the Medical Ethics Committee of Maastricht University and Maastricht University Hospital, the Netherlands, and were conducted in accordance with the Declaration of Helsinki. Participants gave written informed consent.
Results
Overall, methylation levels of the four investigated CpG sites were low. Individual percentages ranged from 0% to 8.74%. Mean methylation (± SD) was as follows: CpG1 2.30±1.63, CpG2 3.64±1.94, CpG3 1.46±1.46, and CpG4 3.05±1.89. Linear regression revealed a significant negative association between CpG3 methylation level and changes in fear scores in PD patients (p=0.004, B=−3.729, Beta=−0.233, t=−2.922) (Table 1). CpG1, CpG2 and CpG4 were not significantly associated with fear scores (p
Discussion
This study showed a significant negative association between CO2-induced fear and the degree of CpG3 methylation (chr17:30,236,084) in the regulatory region of the SLC6A4 gene in PD patients, in line with our hypothesis. In our previous genetic study, we observed a higher fear response to CO2 in 5-HTTLPR LL-allele carriers (Schruers et al., 2011) who presumably have a higher 5-HTT expression. The 5-HTT is located on presynaptic 5-HT neurons and is responsible for reuptake of extracellular 5-HT.
CRediT authorship contribution statement
N.K. Leibold: Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing - original draft. M.T. Weidner: Conceptualization, Formal analysis, Investigation, Methodology, Writing - review & editing. C. Ziegler: Methodology, Writing - review & editing. G. Ortega: Investigation, Methodology, Writing - review & editing. K. Domschke: Methodology, Writing - review & editing. K.P. Lesch: Conceptualization, Methodology, Project administration, Supervision, Writing - review &
Role of funding source
Klaus-Peter Lesch (KPL) and his team are supported by the Deutsche Forschungsgemeinschaft (DFG: CRU 125, CRC TRR 58 A1/A5, No. 44,541,416), the European Union's Horizon 2020 Research and Innovation Programme under Grant No. 728,018 (Eat2beNICE), ERA-Net NEURON/RESPOND,No. 01EW1602B, and 5–100 Russian Academic Excellence Project. Katharina Domschke (KD) received funding by the German Research Foundation (DFG) – project no. 44,541,416 – TRR 58, subprojects C02 and Z02. The funders had no role in
Contributors
KRS designed the study and wrote the protocol. NKL did the experiments. NKL, MTW, CZ, OG, designed and did the epigenetic analysis. NKL and MTW undertook the statistical analysis, and NKL wrote the first draft of the manuscript. DvdH, KD, and KPL contributed to overall discussion. All authors contributed to and have approved the final manuscript.
Conflict of interest
KPL served as a speaker for Eli Lilly and received research support from Medice, and travel support from Shire, all outside the submitted work. Other authors declare no conflict of interest.
Acknowledgement
None.
References (25)
- et al.
The brain acid-base homeostasis and serotonin: a perspective on the use of carbon dioxide as human and rodent experimental model of panic
Prog. Neurobiol.
(2015) - et al.
DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder
J. Psychiatr. Res.
(2011) - et al.
The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic
Neurosci. Biobehav. Rev.
(2014) - et al.
Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients
Psychiatry Res.
(2000) - et al.
Acute l-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients
Psychiatry Res.
(2002) Diagnostic and Statistical Manual of Mental Disorders-5
(2013)- et al.
Quality of life in panic disorder: looking beyond symptom remission
Qual. Life Res.
(2012) - et al.
Monoamine oxidase a gene DNA hypomethylation - a risk factor for panic disorder?
Int. J. Neuropsychopharmacol.
(2012) - et al.
Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response
Int. J. Neuropsychopharm.
(2014) - et al.
Serotonin transporter gene promoter methylation status correlates with in vivo prefrontal 5-HTT availability and reward function in human obesity
Transl. Psychiatry
(2017)